Best Blood Cancer Hospital in Hyderabad - 11 Centres, NCCN Protocols, NABH-Accredited Partners

No single hospital is automatically best. The most important factors for blood cancer (which covers leukemia, lymphoma, and myeloma) are whether the team is led by a haemato-oncologist, whether the hospital can perform complete bone marrow workup including flow cytometry, cytogenetics and molecular testing, and whether stem cell transplant and CAR-T pathways are accessible. CION meets these criteria with 11 centres across Hyderabad and 1,000+ blood cancer cases per year.

Blood cancer is an umbrella term covering three main groups, each behaving differently. Leukemia starts in the bone marrow and affects blood-cell production. Lymphoma starts in lymph nodes and the lymphatic system. Multiple myeloma starts in the bone marrow but specifically from plasma cells (antibody-producing white blood cells). All three are managed by haemato-oncologists, but the workup, presentation, and treatment differ substantially. Modern treatment has transformed all three — many patients now live for many years with their disease as a chronic condition.

Multiple myeloma is cancer of plasma cells — a type of white blood cell whose normal job is making antibodies against infections. Cancerous plasma cells proliferate in the bone marrow and produce an abnormal protein (called M-protein or paraprotein) that can be detected in blood and urine tests. Myeloma differs from leukemia (which affects blood-cell-producing stem cells) and lymphoma (which affects lymphocytes in lymph nodes). Myeloma is especially known for causing distinctive bone disease — back pain, fractures, and 'lytic' lesions seen on imaging — and is the most common reason for unexplained bone pain in older adults.

Myeloma symptoms are summarised by the 'CRAB' criteria: high Calcium in blood (causing confusion, constipation, increased thirst), Renal (kidney) failure, Anemia (fatigue, breathlessness), and Bone lesions (back pain, fractures from minimal trauma). Recurrent infections are also common because abnormal plasma cells crowd out healthy antibody-making cells. Many patients present with persistent unexplained back pain or a low-impact fracture, which prompts imaging that reveals the underlying disease. Any older adult with unexplained bone pain, recurrent infections, or unexplained anemia should be evaluated.

Outcomes vary substantially by disease and subtype. Per US NCI SEER data: multiple myeloma 5-year survival averages around 58% (improved dramatically with modern triplet/quadruplet therapy and stem cell transplant). Non-Hodgkin lymphoma overall averages around 74%, Hodgkin lymphoma around 89%. Leukemia outcomes vary widely — AML around 30% (highly age- and molecular-feature dependent), ALL approaching 90% in children, CML on TKI therapy near-normal life expectancy, CLL very variable with long survival typical. The hospital you choose directly affects whether you receive the correct disease-specific protocol.

Costs vary by disease and treatment intensity. Indicative ranges across blood cancers: bone marrow biopsy ₹8,000-20,000; flow cytometry ₹8,000-15,000; cytogenetics/FISH ₹15,000-30,000; protein electrophoresis ₹3,000-8,000; whole-body imaging ₹10,000-25,000; VRd induction for myeloma 6 cycles ₹3-8 lakh; daratumumab per cycle ₹70,000-1.5 lakh; ABVD or R-CHOP for lymphoma ₹1.5-5 lakh; AML induction ₹3-8 lakh; imatinib for CML ₹15,000-30,000 per month (generic); maintenance lenalidomide ₹40,000-1 lakh per month; autologous stem cell transplant ₹15-25 lakh; allogeneic transplant ₹25-40 lakh; CAR-T cell therapy ₹50 lakh-1.5 crore. CION provides written estimates before treatment.

Myeloma diagnosis requires a combination of tests. Blood and urine tests look for the abnormal protein (M-protein) via serum and urine protein electrophoresis (SPEP, UPEP) and free light chain assay. Bone marrow biopsy confirms the proportion of abnormal plasma cells and provides material for cytogenetics and FISH testing (which detect high-risk genetic features). Imaging — typically whole-body low-dose CT, sometimes whole-body MRI or PET-CT — looks for the characteristic bone lesions. Blood tests assess calcium, kidney function, and anemia. The combination determines whether the patient has MGUS (precursor), smoldering myeloma (intermediate), or active myeloma (needing treatment).

For transplant-eligible patients with newly diagnosed multiple myeloma — typically those under about 70 years of age and reasonably fit — autologous stem cell transplant after initial induction therapy remains a standard part of treatment. The patient's own stem cells are collected and stored, then given back after high-dose chemotherapy. Transplant deepens the response achieved by induction and extends the duration of remission. After transplant, maintenance therapy with lenalidomide continues for years. For patients who are not transplant-eligible because of age or other health issues, modern non-transplant regimens give very good outcomes. CION coordinates transplant through NABH-accredited partner centres.

Yes — CAR-T cell therapy is now available in India through select centres for several blood cancers: relapsed or refractory B-cell Acute Lymphoblastic Leukemia, relapsed or refractory diffuse large B-cell lymphoma, and relapsed multiple myeloma. The patient's own immune T-cells are collected, genetically modified in a laboratory to recognise and attack the cancer, and given back. CAR-T is expensive, requires specialised facilities, and is not first-line therapy for any blood cancer — but for patients who need it, it offers a chance of cure or prolonged disease control when other treatments have failed. Bispecific antibodies (a related approach) are also emerging. CION coordinates these therapies through NABH-accredited partner centres.

Many qualified hospitals are empanelled for ArogyaSri and most major cashless insurers, but empanelment varies by centre and procedure. Stem cell transplant, CAR-T cell therapy, and newer targeted drugs (daratumumab, isatuximab, carfilzomib, pomalidomide, bispecific antibodies) have specific scheme rules and may have caps. Generic imatinib for CML and generic lenalidomide for myeloma have made some treatments more affordable. CION is empanelled for ArogyaSri and accepts most major insurers and TPAs. Request a written cost estimate and confirm pre-authorisation before treatment begins.